The appraisals of apalutamide for treating metastatic hormone-sensitive prostate cancer [ID1534] and apalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1174] have been combined into a single appraisal with the title apalutamide for treating prostate cancer [ID1534]. Please refer to https://www.nice.org.uk/guidance/indevelopment/gid-ta10423 for further information on this combined appraisal.